Petrus Bekker Net Worth

The estimated Net Worth of Petrus Bekker is at least $3.92 Milion dollars as of 11 July 2017. Petrus Bekker owns over 76,013 units of ChemoCentryx Inc stock worth over $3,741,408 and over the last 13 years Petrus sold CCXI stock worth over $179,100.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Petrus Bekker CCXI stock SEC Form 4 insiders trading

Petrus has made over 26 trades of the ChemoCentryx Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Petrus exercised 76,013 units of CCXI stock worth $532,091 on 11 July 2017.

The largest trade Petrus's ever made was exercising 76,013 units of ChemoCentryx Inc stock on 11 July 2017 worth over $532,091. On average, Petrus trades about 12,595 units every 55 days since 2012. As of 11 July 2017 Petrus still owns at least 71,964 units of ChemoCentryx Inc stock.

You can see the complete history of Petrus Bekker stock trades at the bottom of the page.

What's Petrus Bekker's mailing address?

Petrus's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW, CA, 94043.

Insiders trading at ChemoCentryx Inc

Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta a (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.

What does ChemoCentryx Inc do?

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Complete history of Petrus Bekker stock trades at ChemoCentryx Inc

ChemoCentryx Inc executives and stock owners

ChemoCentryx Inc executives and other stock owners filed with the SEC include:

• Thomas Schall,
  Chairman of the Board, President, Chief Executive Officer
• Susan Kanaya,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary
• Markus Cappel,
  Chief Business Officer, Treasurer
• Dr. Thomas J. Schall Ph.D.,
  Founder, Pres, CEO & Chairman
• Susan M. Kanaya,
  Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
• Dr. Markus J. Cappel Ph.D.,
  Sr. VP, Chief Bus. Officer & Treasurer
• Rita Jain,
  Independent Director
• James Tyree,
  Independent Director
• Henry McKinnell,
  Independent Director
• Thomas Edwards,
  Independent Director
• Joseph Feczko,
  Independent Director
• Geoffrey Parker,
  Independent Director
• Dr. Rita I. Jain M.D.,
  Exec. VP, Chief Medical Officer & Exec. Employee Director
• Dr. Sangita Ghosh Ph.D.,
  Sr. VP of Technical Operations
• Dalia R. Rayes,
  Sr. VP & Head of Commercial
• Kari E. Leetch,
  Sr. VP of HR
• Tausif Butt,
  Exec. VP & COO
• Roger C Lucas,
  Director
• Petrus Bekker,
  SVP of Medical & Clinical
• Rajinder Singh,
  SVP, Research
• Partners L P/Ilbiotechnolog...,
  
• Jennifer Lyn Herron,
  Director
• Pui San Kwan,
  Principal Acctg Officer
• William Fairey,
  Chief Operating Officer
• Plc Gsk,
  10% owner
• Edward Penhoet,
  Director
• Ira Klein,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Anne Marie Duliege,
  EVP, Chief of Strategic Dev.
• Israel Charo,
  SVP, Research
• Juan C. Jaen,
  SVP, Drug Discovery & CSO
• Tausif Butt,
  EVP, Chief Operating Officer
• Partners L P/Ilbvf Investme...,
  
• Corp /Mn/ Techne,
  10% owner
• Advisors Llcorbimed Capital...,
  
• Rishi Gupta,
  Director
• (International) Ltd Vifor P...,
  
• Yi Ching Yau,
  SVP, Finance & Acctg Officer
• David E. Wheadon,
  Director